| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2022 | AKBA Akebia Therapeutics, Inc. | Cotreau Violetta | SVP, Chief Accounting Officer | Sell | 3,946 | $2.15 | $8,502.84 | -11.9% | -82.9% | -61.0% | |
| Feb 25, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, EVP &Treasurer | Sell | 23,000 | $28.47 | $654,850.00 | -9.3% | +25.8% | +13.1% | |
| Feb 25, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | EVP, Production Center | Sell | 13,246 | $28.77 | $381,087.42 | -15.9% | +25.8% | +13.1% | |
| Feb 25, 2022 | LLY Eli Lilly & Co | Zakrowski Donald A | Chief Accounting Officer | Sell | 1,660 | $243.84 | $404,774.40 | -18.6% | +25.4% | +29.4% | |
| Feb 25, 2022 | ZTS Zoetis Inc. | Peck Kristin C66 | Chief Executive Officer | Sell | 10,000 | $192.29 | $1,922,908.00 | -10.5% | -14.6% | -14.1% | |
| Feb 25, 2022 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 25,000 | $0.20 | $5,000.00 | -0.1% | - | - | |
| Feb 25, 2022 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | Chief Administrative Officer | Sell | 2,060 | $67.01 | $138,040.00 | -2.9% | -7.4% | -38.9% | |
| Feb 24, 2022 | BMY Bristol Myers Squibb Co | Caforio Giovanni59 | Board Chair And CEO | Sell | 30,000 | $67.00 | $2,010,000.00 | -6.2% | +16.0% | +6.9% | |
| Feb 23, 2022 | ALKS Alkermes Plc. | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sell | 11,983 | $24.76 | $296,649.95 | -40.0% | +17.5% | +13.4% | |
| Feb 23, 2022 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 25,000 | $0.20 | $5,002.50 | -0.1% | - | - | |
| Feb 23, 2022 | ZTS Zoetis Inc. | David Glenn | Executive Vice President | Sell | 32,390 | $189.87 | $6,149,881.25 | -15.9% | -12.7% | -8.9% | |
| Feb 18, 2022 | ALKS Alkermes Plc. | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sell | 2,306 | $25.17 | $58,042.02 | -19.5% | +17.5% | +11.9% | |
| Feb 18, 2022 | COLL Collegium Pharmaceutical, Inc | Dreyer Scott54 | EVP &Chief Commercial Officer | Sell | 10,559 | $21.61 | $228,179.99 | -8.0% | -26.5% | +24.9% | |
| Feb 17, 2022 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $202.17 | $1,213,023.67 | -4.5% | -7.3% | +27.9% | |
| Feb 16, 2022 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 15,000 | $0.22 | $3,309.00 | - | - | - | |
| Feb 16, 2022 | LLY Eli Lilly & Co | Yuffa Ilya | SVP &President, Lly Int'l | Sell | 2,000 | $240.02 | $480,030.00 | -7.6% | +23.1% | +34.0% | |
| Feb 15, 2022 | BCRX Biocryst Pharmaceuticals Inc | Abercrombie George B68 | Director | Sell | 5,000 | $18.50 | $92,500.00 | -100% | -54.7% | -45.8% | |
| Feb 15, 2022 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 1,241 | $28.64 | $35,542.24 | -2.0% | +130.3% | +106.7% | |
| Feb 15, 2022 | ZTS Zoetis Inc. | Lagano Roxanne70 | Executive Vice President | Sell | 2,065 | $196.54 | $405,855.10 | -8.0% | -16.2% | -11.0% | |
| Feb 15, 2022 | BHC Bausch Health Companies Inc. | Spurr Robert82 | U.s. President-pharma Business | Sell | 3,251 | $25.02 | $81,340.02 | -5.1% | -57.8% | -64.8% | |
| Feb 11, 2022 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 20,000 | $0.22 | $4,400.00 | - | - | - | |
| Feb 10, 2022 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | Chief Administrative Officer | Sell | 800 | $65.18 | $52,144.00 | -3.5% | -6.9% | -37.9% | |
| Feb 9, 2022 | TEVA Teva Pharmaceutical Industries Ltd | Drape Eric51 | Executive VP Global Operations | Sell | 3,583 | $9.06 | $32,463.77 | -9.0% | -16.7% | +9.2% | |
| Feb 9, 2022 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 13,135 | $9.06 | $119,009.67 | -39.3% | -16.7% | +9.2% | |
| Feb 9, 2022 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 6,116 | $9.06 | $55,412.18 | -10.6% | -16.7% | +9.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.